caa a22 4500 467934940 CHVBK 20180406152954.0 cr unu---uuuuu 170328e20061001xx s 000 0 eng 10.1007/s00408-005-2594-8 doi (NATIONALLICENCE)springer-10.1007/s00408-005-2594-8 Achieving Full-Dose, On-Schedule Administration of ACE Chemotherapy Every 14 Days for the Treatment of Patients with Extensive Small-Cell Lung Cancer [Elektronische Daten] [R. Pirker, E. Ulsperger, J. Messner, K. Aigner, B. Forstner, P. Bacon, V. Easton, T. Skacel] Extensive small-cell lung cancer (SCLC) is commonly treated with multiple cycles of chemotherapy. Reducing the time interval between cycles of chemotherapy (dose-dense chemotherapy) may improve outcomes in the treatment of extensive SCLC, as it has in other chemosensitive malignancies. To evaluate the feasibility of dose-dense chemotherapy in patients with extensive SCLC, this study evaluates a dose-dense doxorubicin/cyclophosphamide/etoposide (ACE) regimen, supported by the once-per-cycle administration of the hematopoietic growth factor pegfilgrastim. Patients received up to six 14-day cycles of ACE chemotherapy (doxorubicin 40 mg/m,2 cyclophosphamide 1000 mg/m2, etoposide 120 mg/m2 on day 1 IV, plus oral etoposide 240 mg/m2 daily on days 2-3). On day 4 of each cycle, patients received pegfilgrastim 6 mg by subcutaneous injection. Of 30 patients enrolled, 27 started chemotherapy and received pegfilgrastim. Full-dose, on-schedule chemotherapy was given to all 22 patients starting cycle 2, and in 107 (88%) of 121 cycles. Eighteen of the 27 patients (67%) received full-dose, on-schedule chemotherapy for all 6 cycles. The overall response rate was 17/27 (63%). Nine patients (33%) experienced hematologic toxicities that investigators considered severe or life-threatening. Four patients (15%) had febrile neutropenia. Full-dose, on-schedule dose-dense ACE chemotherapy is feasible with once-per-cycle pegfilgrastim support in extensive SCLC. Springer Science+Business Media, Inc., 2006 Small-cell lung cancer nationallicence Febrile neutropenia nationallicence Pegfilgrastim nationallicence Hematopoietic growth factor nationallicence Dose density nationallicence Pirker R. Division of Oncology, Department of Internal Medicine I, Medical University Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria aut Ulsperger E. Fifth Medical Department, Lainz Hospital, Wolkersbergenstrasse 1, A-1130, Vienna, Austria aut Messner J. Division of Lung Diseases, General Hospital, Auerspergstrasse 10, A-5020, Salzbuxg, Austria aut Aigner K. Pneumological Division, Elisabethinen Hospital, Fadingerstrasse 1, A-4010, Linz, Austria aut Forstner B. Pneumological Division, Elisabethinen Hospital, Fadingerstrasse 1, A-4010, Linz, Austria aut Bacon P. Amgen Europe, Amgen International, Dammstrasse 23, 6300, Zug, Switzerland aut Easton V. Amgen Development Europe, 240 Cambridge Science Park, Milton Road, CB4 OWD, Cambridge, United Kingdom aut Skacel T. Amgen Europe, Amgen International, Dammstrasse 23, 6300, Zug, Switzerland aut Lung Springer-Verlag; www.springer-ny.com 184/5(2006-10-01), 279-285 0341-2040 184:5<279 2006 184 408 https://doi.org/10.1007/s00408-005-2594-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00408-005-2594-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Pirker R. Division of Oncology, Department of Internal Medicine I, Medical University Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria aut NATIONALLICENCE 700 1- Ulsperger E. Fifth Medical Department, Lainz Hospital, Wolkersbergenstrasse 1, A-1130, Vienna, Austria aut NATIONALLICENCE 700 1- Messner J. Division of Lung Diseases, General Hospital, Auerspergstrasse 10, A-5020, Salzbuxg, Austria aut NATIONALLICENCE 700 1- Aigner K. Pneumological Division, Elisabethinen Hospital, Fadingerstrasse 1, A-4010, Linz, Austria aut NATIONALLICENCE 700 1- Forstner B. Pneumological Division, Elisabethinen Hospital, Fadingerstrasse 1, A-4010, Linz, Austria aut NATIONALLICENCE 700 1- Bacon P. Amgen Europe, Amgen International, Dammstrasse 23, 6300, Zug, Switzerland aut NATIONALLICENCE 700 1- Easton V. Amgen Development Europe, 240 Cambridge Science Park, Milton Road, CB4 OWD, Cambridge, United Kingdom aut NATIONALLICENCE 700 1- Skacel T. Amgen Europe, Amgen International, Dammstrasse 23, 6300, Zug, Switzerland aut NATIONALLICENCE 773 0- Lung Springer-Verlag; www.springer-ny.com 184/5(2006-10-01), 279-285 0341-2040 184:5<279 2006 184 408 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer